Overview
Description
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 7,269 m |
| EPS, EUR | 2.40 |
| P/B ratio | 38.2 |
| P/E ratio | 25.4 |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 1,238 m |
| Net income, EUR | 281 m |
| Profit margin | 22.69% |
What ETF is Halozyme Therapeutics in?
There are 4 ETFs which contain Halozyme Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Halozyme Therapeutics is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.61% | Equity United States Health Care Biotech | 46 |
| Vanguard ESG Global All Cap UCITS ETF (USD) Distributing | 0.01% | Equity World Social/Environmental | 534 |
| Vanguard ESG North America All Cap UCITS ETF (USD) Distributing | 0.01% | Equity North America Social/Environmental | 26 |
| JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) | 0.13% | Equity United States Small Cap | 216 |
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
